Promising Pathway Act

The Promising Pathway Act creates a new FDA review pathway for drugs treating serious or life-threatening conditions, allowing provisional approval within 90 days if they show substantial safety evidence and early efficacy comparable to existing treatments. It directly affects drug manufacturers (sponsors), patients with urgent medical needs, and insurers, requiring mandatory patient registries tracking outcomes and side effects with a 90% participation goal. The bill mandates that insurers cover these provisionally approved drugs as if fully approved (without denying coverage as "experimental") and requires sponsors to submit annual reports to Congress on registry data and approval progress. Provisional approval lasts up to 8 years (2 years initially, renewable up to three times) but requires market launch within 180 days and allows FDA withdrawal if safety concerns arise or efficacy falls below standard treatments.